Premium
Adjuvant Topical Chemotherapy versus Immunotherapy in Primary Superficial Transitional Cell Carcinoma of the Bladder
Author(s) -
FLAMM J.,
BUCHER A.
Publication year - 1991
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1991.tb15072.x
Subject(s) - medicine , transitional cell carcinoma , adjuvant , chemotherapy , surgery , keyhole limpet hemocyanin , stage (stratigraphy) , immunotherapy , urology , carcinoma , prospective cohort study , bladder cancer , cancer , immune system , immunology , paleontology , biology
Summary— In a prospective randomised controlled study, the efficacy of ethoglucid was compared with that of keyhole‐limpet haemocyanin (KLH) in preventing recurrent tumours following transurethral resection of primary superficial transitional cell carcinoma of the bladder. Patients treated with ethoglucid (n = 39) received 0.565 g (1% solution) ethoglucid weekly for 6 weeks and then monthly for 1 year. Patients treated with KLH (n = 38) were immunised subcutaneously with 1 mg KLH; bladder instillations of 30 mg were then given weekly for 6 weeks and thereafter monthly for 1 year. The recurrence rates, disease‐free intervals and tumour progression rates were evaluated. The end‐point of the study was either progression in stage or grade or more than 1 recurrence during the observation period. The minimum length of follow‐up was 1 year. The recurrence rates, mean disease‐free intervals and progression rates in the 2 groups snowed no statistically significant differences.